


Op 1653

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: O'Brien, et al.

ART UNIT: 1653

FILED: August 21, 1997



SERIAL NO.: 08/915,659
G.

EXAMINER:

Bugaisky,

FOR: Novel Extracellular
Serine Protease

DOCKET: D 6020

RECEIVED

NOV 12 1999

TECH CENTER 1600/2900

The Assistant Commissioner of Patents and Trademarks
Box NON-FEE AMENDMENT
Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

Dear Sir:

I hereby certify under 37 CFR 1.8 that the following correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to Commissioner of Patents and Trademarks, Washington DC 20231.

- 1) Response to Office Action (5 Pages); and,
- 2) Return postcard.

Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

Date: 11/8/99
McGREGOR & ADLER, LLP
8011 Candle Lane
Houston, Texas 77071
(713) 777-2321

Benjamin Aaron Adler, Ph.D., J.D.
Counsel for Applicant
Registration No. 35,423

#17 11/23/99
And HF

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: O'Brien, et al.

ART UNIT: 1653

FILED: August 21, 1997

EXAMINER:

SERIAL NO.: 08/915,659

Bugaisky, G.

FOR: Novel Extracellular
Serine Protease

DOCKET: D 6020

The Assistant Commissioner of Patents and Trademarks
BOX NON-FEE AMENDMENT
Washington, DC 20231

RESPONSE UNDER 37 C.F.R. § 1.111

Dear Sir:

In response to the Office Action mailed August 18, 1999,
please enter the following amendments and remarks.
Reconsideration of the pending claims as amended is respectfully
requested.

IN THE CLAIMS:

Please amend claim 1 as follows:

F1
1. (fourth amendment) DNA encoding a Tumor
Antigen Derived Gene-14 (TADG-14) protein, wherein said protein
has the amino acid sequence shown in SEQ ID No: 7, and wherein said
DNA is selected from the group consisting of: